Treating high-risk, statin-intolerant patients without a prior cardiovascular event with bempedoic acid (Nexletol; Esperion) leads to a significant reduction in their risk of atherosclerotic ...
Philadelphia, December 14, 2023 – The updated Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) antiplatelet therapy guidelines for primary and secondary ...
Taking into account estimated 30-year risk of atherosclerotic cardiovascular disease (ASCVD) enables clinicians to identify ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Please provide your email address to receive an email when new articles are posted on . In the new PREVENT heart disease risk calculator, fewer U.S. adults were eligible for primary prevention statin ...
Share on Pinterest A study found that a large number of patients do not receive recommended treatment for atherosclerotic cardiac disease (ASCVD). Denis Kirichkov/Stocksy In 2013, new guidelines were ...
Estimates from the Predicting Risk of Cardiovascular Disease EVENT (PREVENT) equations identified substantially fewer individuals eligible to receive aspirin for the primary prevention of ...
SAN DIEGO – A new analysis of a large-scale trial of a novel lipid-lowering agent has shown a particularly large reduction in cardiovascular events in the primary prevention population enrolled in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results